​

ZyVersa Therapeutics Stock (NASDAQ:ZVSA)

FinancialsChart
ZyVersa Therapeutics by TradingView

Previous Close

$0.20

52W Range

$0.11 - $1.67

50D Avg

$0.23

200D Avg

$0.18

Market Cap

$1.70M

Avg Vol (3M)

$25.95K

Beta

0.70

Div Yield

-

ZVSA Company Profile

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

7

IPO Date

Feb 11, 2022

Website

ZVSA Performance

ZVSA Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-25.49B$-9.14B$-14.42M
Net Income$-24.95B$-9.41B$-98.30M
EBITDA$-25.49B$-9.14B$-107.74M
Basic EPS$-4.18$-8.48$-1.09K
Diluted EPS$-4.18$-8.48$-1.09K

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
XAGELongevity Health Holdings Inc.
WORXSCWorx Corp.
JSPRJasper Therapeutics, Inc.
CDTCDT Equity Inc.
ONCOOnconetix, Inc.
SLXNSilexion Therapeutics Ltd.
INDPIndaptus Therapeutics, Inc.
NIVFNewGenIvf Group Limited
ENVBEnveric Biosciences, Inc.